Accounting for leadtime in cohort studies: Evaluating when to initiate HIV therapies

Stephen R. Cole, Rui Li, Kathryn Anastos, Roger Detels, Mary Young, Joan S. Chmiel, Alvaro Muñoz

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Commonly reported comparisons of differences in disease progression according to disease staging at therapy initiation may be subject to bias if they do not account for the time it took the deferred group to reach the latter stage (that is, leadtime) and for previous events in those who initiate therapy at late stage (that is, unseen fast progressors). To estimate the impact of deferring initiation of highly active antiretroviral therapies (HAART) on time to clinical AIDS in the context of data from observational cohort studies, we describe a method that capitalizes on data from a pre-HAART period to multiply impute estimated leadtimes and the unseen events among fast progressors. After accounting for leadtime and the unseen events, data from two large cohort studies (N=739) indicate that deferring HAART initiation until CD4 is below 200 cells/mm3 was detrimental compared to initiating between 201 and 350 (hazard ratio=1.97;95 per cent confidence interval [CI] 1.09, 3.54), and that failure to account for leadtime resulted in a 38 per cent higher hazard ratio. In contrast, initiating HAART between 201 and 350 did not increase the hazard of AIDS compared to initiating with CD4 between 351 and 500cells/mm3 (hazard ratio=0.70;95 per cent CI 0.35, 1.42). Methods presented here offer an approach to analysing prevalent cohort studies and provide procedures to maximize the usefulness of observational data.

Original languageEnglish (US)
Pages (from-to)3351-3363
Number of pages13
JournalStatistics in Medicine
Volume23
Issue number21
DOIs
StatePublished - Nov 15 2004
Externally publishedYes

Fingerprint

Cohort Study
Highly Active Antiretroviral Therapy
Therapy
Cohort Studies
HIV
Hazard
Acquired Immunodeficiency Syndrome
Confidence Intervals
Confidence interval
Therapeutics
Observational Studies
Disease Progression
Progression
Multiplication
Maximise
Cell
Estimate

Keywords

  • AIDS
  • Bias
  • Cohort study
  • HIV
  • Multiple imputation

ASJC Scopus subject areas

  • Epidemiology

Cite this

Cole, S. R., Li, R., Anastos, K., Detels, R., Young, M., Chmiel, J. S., & Muñoz, A. (2004). Accounting for leadtime in cohort studies: Evaluating when to initiate HIV therapies. Statistics in Medicine, 23(21), 3351-3363. https://doi.org/10.1002/sim.1579

Accounting for leadtime in cohort studies : Evaluating when to initiate HIV therapies. / Cole, Stephen R.; Li, Rui; Anastos, Kathryn; Detels, Roger; Young, Mary; Chmiel, Joan S.; Muñoz, Alvaro.

In: Statistics in Medicine, Vol. 23, No. 21, 15.11.2004, p. 3351-3363.

Research output: Contribution to journalArticle

Cole, SR, Li, R, Anastos, K, Detels, R, Young, M, Chmiel, JS & Muñoz, A 2004, 'Accounting for leadtime in cohort studies: Evaluating when to initiate HIV therapies', Statistics in Medicine, vol. 23, no. 21, pp. 3351-3363. https://doi.org/10.1002/sim.1579
Cole, Stephen R. ; Li, Rui ; Anastos, Kathryn ; Detels, Roger ; Young, Mary ; Chmiel, Joan S. ; Muñoz, Alvaro. / Accounting for leadtime in cohort studies : Evaluating when to initiate HIV therapies. In: Statistics in Medicine. 2004 ; Vol. 23, No. 21. pp. 3351-3363.
@article{960b515f50064e0dbda9ecad2b6764ae,
title = "Accounting for leadtime in cohort studies: Evaluating when to initiate HIV therapies",
abstract = "Commonly reported comparisons of differences in disease progression according to disease staging at therapy initiation may be subject to bias if they do not account for the time it took the deferred group to reach the latter stage (that is, leadtime) and for previous events in those who initiate therapy at late stage (that is, unseen fast progressors). To estimate the impact of deferring initiation of highly active antiretroviral therapies (HAART) on time to clinical AIDS in the context of data from observational cohort studies, we describe a method that capitalizes on data from a pre-HAART period to multiply impute estimated leadtimes and the unseen events among fast progressors. After accounting for leadtime and the unseen events, data from two large cohort studies (N=739) indicate that deferring HAART initiation until CD4 is below 200 cells/mm3 was detrimental compared to initiating between 201 and 350 (hazard ratio=1.97;95 per cent confidence interval [CI] 1.09, 3.54), and that failure to account for leadtime resulted in a 38 per cent higher hazard ratio. In contrast, initiating HAART between 201 and 350 did not increase the hazard of AIDS compared to initiating with CD4 between 351 and 500cells/mm3 (hazard ratio=0.70;95 per cent CI 0.35, 1.42). Methods presented here offer an approach to analysing prevalent cohort studies and provide procedures to maximize the usefulness of observational data.",
keywords = "AIDS, Bias, Cohort study, HIV, Multiple imputation",
author = "Cole, {Stephen R.} and Rui Li and Kathryn Anastos and Roger Detels and Mary Young and Chmiel, {Joan S.} and Alvaro Mu{\~n}oz",
year = "2004",
month = "11",
day = "15",
doi = "10.1002/sim.1579",
language = "English (US)",
volume = "23",
pages = "3351--3363",
journal = "Statistics in Medicine",
issn = "0277-6715",
publisher = "John Wiley and Sons Ltd",
number = "21",

}

TY - JOUR

T1 - Accounting for leadtime in cohort studies

T2 - Evaluating when to initiate HIV therapies

AU - Cole, Stephen R.

AU - Li, Rui

AU - Anastos, Kathryn

AU - Detels, Roger

AU - Young, Mary

AU - Chmiel, Joan S.

AU - Muñoz, Alvaro

PY - 2004/11/15

Y1 - 2004/11/15

N2 - Commonly reported comparisons of differences in disease progression according to disease staging at therapy initiation may be subject to bias if they do not account for the time it took the deferred group to reach the latter stage (that is, leadtime) and for previous events in those who initiate therapy at late stage (that is, unseen fast progressors). To estimate the impact of deferring initiation of highly active antiretroviral therapies (HAART) on time to clinical AIDS in the context of data from observational cohort studies, we describe a method that capitalizes on data from a pre-HAART period to multiply impute estimated leadtimes and the unseen events among fast progressors. After accounting for leadtime and the unseen events, data from two large cohort studies (N=739) indicate that deferring HAART initiation until CD4 is below 200 cells/mm3 was detrimental compared to initiating between 201 and 350 (hazard ratio=1.97;95 per cent confidence interval [CI] 1.09, 3.54), and that failure to account for leadtime resulted in a 38 per cent higher hazard ratio. In contrast, initiating HAART between 201 and 350 did not increase the hazard of AIDS compared to initiating with CD4 between 351 and 500cells/mm3 (hazard ratio=0.70;95 per cent CI 0.35, 1.42). Methods presented here offer an approach to analysing prevalent cohort studies and provide procedures to maximize the usefulness of observational data.

AB - Commonly reported comparisons of differences in disease progression according to disease staging at therapy initiation may be subject to bias if they do not account for the time it took the deferred group to reach the latter stage (that is, leadtime) and for previous events in those who initiate therapy at late stage (that is, unseen fast progressors). To estimate the impact of deferring initiation of highly active antiretroviral therapies (HAART) on time to clinical AIDS in the context of data from observational cohort studies, we describe a method that capitalizes on data from a pre-HAART period to multiply impute estimated leadtimes and the unseen events among fast progressors. After accounting for leadtime and the unseen events, data from two large cohort studies (N=739) indicate that deferring HAART initiation until CD4 is below 200 cells/mm3 was detrimental compared to initiating between 201 and 350 (hazard ratio=1.97;95 per cent confidence interval [CI] 1.09, 3.54), and that failure to account for leadtime resulted in a 38 per cent higher hazard ratio. In contrast, initiating HAART between 201 and 350 did not increase the hazard of AIDS compared to initiating with CD4 between 351 and 500cells/mm3 (hazard ratio=0.70;95 per cent CI 0.35, 1.42). Methods presented here offer an approach to analysing prevalent cohort studies and provide procedures to maximize the usefulness of observational data.

KW - AIDS

KW - Bias

KW - Cohort study

KW - HIV

KW - Multiple imputation

UR - http://www.scopus.com/inward/record.url?scp=2442711053&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2442711053&partnerID=8YFLogxK

U2 - 10.1002/sim.1579

DO - 10.1002/sim.1579

M3 - Article

C2 - 15493031

AN - SCOPUS:2442711053

VL - 23

SP - 3351

EP - 3363

JO - Statistics in Medicine

JF - Statistics in Medicine

SN - 0277-6715

IS - 21

ER -